Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hepatitis Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hepatitis Other
    HBeAg-Positive Pregnant Women With HBV DNA Warrant Further Assessment to Prevent Transmission to Infant: Presented at ICC - (DGDispatch)
    Persistent Immune Memory, Lasting Seroprotection Observed in Infants Immunised With a Monovalent HBV Vaccine: Presented at ESPID - (DGDispatch)
    Coadministration of Quadrivalent HPV Vaccine and Hepatitis A/B Vaccine in Girls Safe, Well Tolerated: Presented at IPV - (DGDispatch)
    Corticosteroid Improves Survival Rates in Patients With Severe Alcoholic Hepatitis: Presented at EASL - (DGDispatch)
    HAART Is Well Tolerated, Leads to Rapid Suppression of HBV Replication in HBV-HIV Coinfected Patients: Presented at EASL - (DGDispatch)

    News archive

     Recent webcasts/CME - Hepatitis Other
      HBV-HIV Co-infection
      HBV in Pregnancy
      Debate: Monotherapy vs. Multiple Drug Therapy as the Wave of the Future for HBV Infection
      Hepatitis B Treatment: Current Best Practices How to Avoid Resistance
      Understanding Cultural Barriers

      Webcasts/CME archive

       Recent cases - Hepatitis Other
        Patient with Hepatitis B and Rheumatoid Arthritis
        Clearing Off Wisconsin Solution Used in Liver Transplantation in Pediatric Patients
        Peritoneal Tuberculosis and Granulomatous Hepatitis Secondary to Treatment of Bladder Cancer with Bacillus Calmette-Guerin
        Fatal Fulminant Herpes Simplex Hepatitis Secondary to Tongue Piercing in an Immunocompetent Adult: A Case Report
        Severe Hepatitis with Autoimmune Features Following a HHV-6: A Case Report

        Cases archive
          




        my personal edition > hepatitis other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Long-Term Efficacy Shown With Entecavir for Patients With Chronic Hepatitis B: Presented at AASLD

          By Arushi Sinha

          SAN FRANCISCO -- November 6, 2008 -- Entecavir treatment appears to result in high rates of viral suppression in patients with chronic hepatitis B virus (HBV) infection, according to research presented here at the Liver Meeting 2008, the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

          One of the challenges in the process of developing effective therapies for patients with chronic HBV is translating agents from clinical trials into clinical practice, said lead investigator Pietro Lampertico, MD, Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Policlinico, Mangiagalli, Regina Elena, University of Milan, Milan, Italy.

          "This is the first study looking at the effectiveness of this therapy in field practice," he explained during his presentation on November 2 on behalf of the research team.

          The study enrolled 182 patients who were diagnosed with chronic hepatitis B at 9 liver centres across Italy. Patients were treated with the oral nucleoside analogue entecavir 0.5 mg for 1 year.

          Patients were aged a median of 57 years (male, 74%), 83% were hepatitis B e antigen (HBeAg)-positive, and 47% were diagnosed with cirrhosis. Patients were tested for liver function and HBV DNA loads at 3-month intervals.

          Results showed that 68% of patients achieved undetectable levels of HBV DNA at 24 weeks and increased to 85% at 48 weeks. Rates of DNA clearance among HBeAg-positive patients were 75% at 24 weeks and 80% at 48 weeks, and for HBeAg-negative patients they were 30% at 24 weeks and 54% at 48 weeks.

          It was also found that patients who exhibited a high viral load (>8 log U/mL) at baseline were more likely to have incomplete responses at 24 weeks (33% vs 70%) and at 48 weeks (40% vs 90%) compared with patients with lower viral loads (P < .01).

          In terms of genetic profiles, the researchers found that 22% of patients had mutations at baseline that had the potential to influence clinical outcomes.

          Based on these findings, the researchers concluded that entecavir treatment resulted in high rates of HBV suppression, noting that patients with a high viral load at baseline were more likely to exhibit an incomplete response after 48 weeks of treatment. In addition, genetic mutations did not seem to influence the clinical outcomes of this therapy.

          "We found that the rates of mutation in general practice have been similar to those we have seen in clinical trials," summarised Dr. Lampertico.


          [Presentation title: Effectiveness of Entecavir for the Treatment of NUC-Naïve Chronic Hepatitis B Patients: A Large Multicenter Cohort Study in Clinical Practice. Abstract 896]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send